Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 2, 2010, Pages 103-114

  Best, Jennie H ^a   Garrison, Louis P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Capecitabine; Chemotherapy; Colon cancer; Colorectal cancer; Economics

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

CANCER ADJUVANT THERAPY; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HOSPITALIZATION COST; HUMAN; METASTASIS; OVERALL SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COST SAVINGS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; NEOPLASM METASTASIS; PRODRUGS;

EID: 77951017770     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.12     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 57, 43-66 (2009).
2. Benson AB, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004). (Pubitemid 41103700)
3. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004). (Pubitemid 38702845)
4. Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ. 17(8), 947-959 (2008).
5. Kerrigan M, Howlader N, Mandelson MT et al. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med. Care 43(10), 1043-1048 (2005). (Pubitemid 41442470)
6. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19, 2282-2292 (2001). (Pubitemid 32366981)
7. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19, 4097-4106 (2001). (Pubitemid 33049527)
8. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, Phase III trials. Eur. J. Cancer 38(Suppl. 2), 15-20 (2002). (Pubitemid 34158853)
9. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26(12), 2006-2012 (2008).
10. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized Phase III noninferiority study. Ann. Oncol. 19(10), 1720-1726 (2008).
11. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352(26), 2696-2704 (2005). (Pubitemid 41007824)
12. Schmoli HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25(1), 102-109 (2007). (Pubitemid 350003057)
13. Haller D, Tabernero J, Maroun J et al. First efficacy findings from a randomized phase III trial of capecitabine oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur. J. Cancer Suppl. 7(3), 4 (2009).
14. Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J. Clin. Oncol. 25(27), 4165-4167 (2007).
15. Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J. Clin. Oncol. 26(13), 2224-2225 (2008).
16. Cassidy J, Schmoll HJ, Cutsem EV. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J. Clin. Oncol. 26(13), 2226-2227 (2008).
17. Almond J, Ralston S. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer 96(9), 1489 (2007). (Pubitemid 46685796)
18. Ferro SA, Myer BS, Debra A, Wolff et al. Variation in the cost of medications for the treatment of colorectal cancer. Am. J. Manag. Care 14(11), 717-725 (2008).
19. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J. Manag. Care Pharm. 12(7), 570-577 (2006).
20. Gorner M, Riemer-Hommel P. Adjuvant chemotherapy for colon cancer - analysis of treatment costs from the perspective of statutory sickness funds. Z. Gastroenterol. 46(7), 681-688 (2008).
21. Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 1115(7), 1412-1423 (2009).
22. Shiroiwa T, Fukuda T. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin. Therapeutics 29(10), 2256-2267 (2007). (Pubitemid 350138568)
23. Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer 115, 2081-2091 (2009).
24. Twelves C. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin. Colorectal Cancer 6(4), 278-287 (2006). (Pubitemid 46157477)
25. Matasar MJ, Sundararajan V, Grann VR et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging 21(2), 113-133 (2004). (Pubitemid 38293789)
26. Jansman FG, Postma MJ, Van Hartskamp D, Willemse PH, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25(7), 537-562 (2007). (Pubitemid 47048039)
27. Krol M, Koopman M, Uyl-De Groot C, Punt CJA. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin. Pharmacother. 8(9), 1313-1328 (2007). (Pubitemid 47034417)
28. Hieke K, Kleeberg UR, Stauch M, Grothey A. Costs of treatment of colorectal cancer in different settings in Germany. Eur. J. Health Econ. 5(3), 270-273 (2004). (Pubitemid 39382527)
29. Grothey A, Kleeberg UR, Stauch M, Hieke K. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z. Gastroenterol. 43(2), 155-161 (2005). (Pubitemid 40332907)
30. Jansman FGA, Postma MJ, Van Hartskamp D, Willemse PHB, Brouwers JRBJ. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin. Ther. 26(4), 579-589 (2004). (Pubitemid 38586459)
31. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastataic colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 7(32), 1-93 (2003). (Pubitemid 37451838)
32. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer 95, 27-34 (2006). (Pubitemid 43980550)
33. Lapatriello S, Amoroso D, Donati S et al. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. Eur. J. Cancer 44(17), 2615-2622 (2008).
34. Caponero R, Ribeiro Rde A, Santos E, Cirrincione A, Saggia M. Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil. J. Med. Econ. 11(2), 311-325 (2008).
35. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br. J. Cancer 101(1), 1195-1201 (2009).
36. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br. J. Cancer 94, 1122-1129 (2006).
37. Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Tech. Assess. 10(41), 1-153 (2006). (Pubitemid 44896104)
38. Eggington S, Tappenden P, Pandor A et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br. J. Cancer 95(9), 1195-1201 (2006). (Pubitemid 44658483)
39. Douillard JY, Tilleul P, Ychou M et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 72(3-4), 248-252 (2007). (Pubitemid 351161618)
40. Di Costanzo F, Ravasio R, Sobrero A et al. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer. Clin. Drug Invest. 28(10), 645-655 (2008).
41. Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin. 25(3), 797-805 (2009).
42. Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology 77, 244-253 (2009).
43. Goerner M, Riemer-Hommel P. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer. Onkologie 32(11), 647-652 (2009).
44. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 13, 566-575 (2002). (Pubitemid 34461140)
45. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol. 14, 1735-1743 (2003). (Pubitemid 38029045)
46. Garrison L, Patel KK, Sengupta N, Green J, Best JH. The cost-effectiveness of capecitabine as adjuvant oral chemotherapy for Duke's C colon cancer. Value Health 8(3), 345 (2005).
47. Garrison L, Cassidy J, Saleh M et al. Cost comparison of XELOX compared to FOLFOX-4 with or without bevacizumab in metastatic colorectal cancer: XELOX vs. FOLFOX-4 bevacizumab. J. Clin. Oncol. 25(Suppl. 188) (2007) (Abstract 4083).
48. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force Report. Value Health 10(5), 326-335 (2007). (Pubitemid 47481104)
49. Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 12(8), 1118-1123 (2009).
50. Lansdorp-Vogelaar I, Van Ballegooijen M, Zauber AG, Habbema JDF, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J. Natl Cancer Inst. 101(20), 1412-1422 (2009).